The global AI in drug discovery market Trends was valued at USD 1.8 Billion in 2024 and is projected to reach USD 14.0 Billion by 2033. The market is expected to grow at a CAGR of 23.17% during the forecast period from 2025 to 2033. Major growth drivers include the exponential increase in biological data, advancements in AI predictive capabilities, cost and time efficiency, and demand for precision medicine across pharmaceuticals, biotechnology, and research sectors.
Study Assumption Years
- Base Year: Not provided in source
- Historical Year/Period: 2019-2024
- Forecast Year/Period: 2025-2033
AI in Drug Discovery Market Key Takeaways
- Current Market Size: USD 1.8 Billion in 2024
- CAGR: 23.17%
- Forecast Period: 2025-2033
- The market is driven by the rising demand for faster and cost-effective drug development to enable quicker identification of drug targets and optimization of clinical trials.
- Services dominate the market due to high demand for AI-driven research that helps reduce costs, improve efficiency, and provide specialized expertise.
- Drug optimization and repurposing hold the largest market share as AI enhances existing drug molecules, thereby reducing development time and costs.
- Oncology leads the therapeutic area segment, driven by the increasing prevalence of cancer and the demand for personalized treatment.
- Pharmaceutical and biotechnology companies hold the largest market share due to substantial investments in AI to enhance drug pipelines and competitiveness.
- North America accounts for the largest market share owing to strong technological infrastructure, leading industry players, and high RD expenditure.
Request for a Free Sample Report: https://www.imarcgroup.com/ai-in-drug-discovery-market/requestsample
Market Growth Factors
Biological and chemical data growth requires more advanced computational tools. These tools analyze molecular structures. They also analyze protein-protein interactions, mutations, and pathways. AI sees wide use in the analysis of complex datasets. It offers perspectives beyond the reach of human researchers. AI reveals patterns and anomalies that might otherwise go disregarded. With these perceptions, the drug discovery process is sped up through the rapid identification of drug candidates by the AI system.
Machine learning, deep learning, and large amounts of data on the history of drug development and testing successes and failures give AI its predictive powers. AI can help generate knowledge through forming hypotheses, predicting effectiveness and side effects of drugs, and sifting large volumes of data to guide research efforts to likely successful compounds. This predictive ability allows for easier drug discovery since less trial and error would be needed.
The high cost and time required for drug discovery and development motivate the integration of AI technologies. AI is used for virtual screening and optimization of compounds and for predicting toxicity, which all reduce time. By selecting compounds more likely to succeed in laboratory testing, more resources can be devoted to those that are more promising, thus avoiding wasted expenditure on those that are less promising, and allowing the pharmaceutical industry to better manage the drug development pipeline, saving time and reducing drug discovery costs.
Market Segmentation
Breakup by Offering:
- Software
- Services
- Services dominate the market due to high demand for AI-driven research services, helping companies reduce costs, improve efficiency, and access specialized expertise.
Breakup by Application:
- Preclinical Testing
- Drug Optimization and Repurposing
- Target Identification
- Candidate Screening
- Others
- Drug optimization and repurposing hold the largest market share as AI enhances existing drug molecules, reduces development time and cost, making this application particularly attractive to pharmaceutical firms.
Breakup by Therapeutic Area:
- Oncology
- Neurodegenerative Diseases
- Cardiovascular Diseases
- Metabolic Diseases
- Others
- Oncology dominates the market owing to rising cancer prevalence and the increasing use of AI tools to identify new therapies and personalize treatments.
Breakup by End User:
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations (CROs)
- Research Centers and Academic Institutes
- Pharmaceutical and biotechnology companies command the largest share, investing heavily in AI to streamline drug discovery and maintain market competitiveness.
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Regional Insights
The North America market holds the largest share in the AI in drug discovery market owing to the larger pharmaceutical and biopharmaceutical industry, increasing investments in AI for drug discovery, good technological infrastructure, the presence of leading companies in the market, and higher RD expenditure. While much of the advances have been in Europe with strong academic and research bases and cross-collaboration, the Asia Pacific region is leading a new charge, with the rapidly emerging biotech industries and governments of China, Japan and India.
Key Players
- Aria Pharmaceuticals Inc.
- Atomwise Inc.
- Benevolent AI
- BioSymetrics Inc
- BPGbio Inc
- Deep Genomics
- Envisagenics
- Euretos
- Evaxion Biotech A/S
- Exscientia
- Insilico Medicine
- NVIDIA Corporation
- Okwin Inc
- XtalPi Inc
Customization Note
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
